Foghorn therapeutics provides first quarter 2022 corporate update

- foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system; both fhd-286 and fhd-609 continue to dose escalate and enroll patients with initial clinical data expected for fhd-286 in h2 2022 and fhd-609 in 2023
FHTX Ratings Summary
FHTX Quant Ranking